DrugDashboards

Furosemide

Furosemide · FUROSEMIDE 10 mg/mL · Injection · Intramuscular; Intravenous · Hikma Pharmaceuticals USA Inc.

NDC 00143-9159-01 · 1 VIAL in 1 CARTON / 100 mL in 1 VIAL · NDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply. The brand price is up 19% over the past year, to $0.2658 per mL. It is in shortage right now — FDA lists the reason as “requirements related to complying with good manufacturing practices”. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.2658per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.0180per billing unit (1 MG)HCPCS J1938 · Jul 1, 2026
  • Part D plans paid (avg)$896.08per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4Jan 2025Sep 2026$0.2658
15 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$20.00
Reported to Texas DSHS · 2026 annual filing · Hikma Pharmaceuticals USA Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$0.018
HCPCS J1938 · Jul 1, 2026 quarter · typically ASP + 6%

Supply fragility

25● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • related presentation in shortage+15
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for furosemide (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · price up 19% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $6.22 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA018267
TE code
AP
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)Apr 7, 2020
    Requirements related to complying with good manufacturing practices
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)Apr 7, 2020
    Requirements related to complying with good manufacturing practices
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
  • In shortage now — Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)Apr 7, 2020
    Requirements related to complying with good manufacturing practices
    month 77 — 4× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Furosemide (Injection)

LabelerStrengthFirst seenLast seen
Hikma Pharmaceuticals USA Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Maiva Pharma Private LimitedFUROSEMIDE 10 mg/mLJul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals LLCFUROSEMIDE 20 mg/2mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCFUROSEMIDE 40 mg/4mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCFUROSEMIDE 100 mg/10mLJul 15, 2026Sep 2, 2026
Civica, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLCFUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Medical Purchasing Solutions, LLC.FUROSEMIDE 10 mg/mLJul 15, 2026Sep 2, 2026
Micro Labs LimitedFUROSEMIDE 100 mg/10mLJul 15, 2026Sep 2, 2026
Micro Labs LimitedFUROSEMIDE 20 mg/2mLJul 15, 2026Sep 2, 2026
Micro Labs LimitedFUROSEMIDE 40 mg/4mLJul 15, 2026Sep 2, 2026
scPharmaceuticals Inc., a wholly owned subsidiary of MannKind CorporationFUROSEMIDE 80 mg/mLJul 29, 2026Sep 2, 2026
SQ Innovation, Inc.FUROSEMIDE 30 mg/mLJul 15, 2026Sep 2, 2026
ten23 health Valais AGFUROSEMIDE 8 mg/mLJul 15, 2026Sep 2, 2026
Accord Healthcare, Inc.FUROSEMIDE 10 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Furosemide — NDC 00143-9159-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00143915901.

Free to cite with attribution — see how the data is put together.